Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study

[1]  Shang-Jyh Hwang,et al.  Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan , 2021, British journal of clinical pharmacology.

[2]  T. Mavrakanas,et al.  Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[3]  L. See,et al.  Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study , 2020, Clinical pharmacology and therapeutics.

[4]  J. Chae,et al.  Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. , 2019, Circulation.

[5]  M. Price,et al.  Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk , 2019, European heart journal.

[6]  Swu-Jane Lin,et al.  Taiwan’s National Health Insurance Research Database: past and future , 2019, Clinical epidemiology.

[7]  M. Banach,et al.  Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations , 2018, BMC Medicine.

[8]  A. Alexandrov,et al.  Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis , 2018, Journal of the Neurological Sciences.

[9]  J. Carrero,et al.  Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function , 2018, Heart.

[10]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[11]  Deepak L. Bhatt,et al.  Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.

[12]  S. Johnston,et al.  Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis , 2017, Circulation.

[13]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. , 2016, Journal of the American College of Cardiology.

[14]  Marc P. Bonaca,et al.  Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) , 2016, Circulation.

[15]  A. Garg,et al.  The Risk of Major Hemorrhage with CKD. , 2016, Journal of the American Society of Nephrology : JASN.

[16]  Ching-Lan Cheng,et al.  Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. , 2015, International journal of cardiology.

[17]  Seung‐Jung Park,et al.  Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[18]  K. Jeong,et al.  Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  G. Lemesle,et al.  Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. , 2014, Journal of the American College of Cardiology.

[20]  Ching-Lan Cheng,et al.  Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan , 2014, Journal of epidemiology.

[21]  Y. Jeong.  “East Asian Paradox”: Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome , 2014, Current Cardiology Reports.

[22]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[23]  R. Kilpatrick,et al.  CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[24]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[25]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[26]  R. Koppensteiner,et al.  Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  R. Teng,et al.  Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment , 2012, Journal of clinical pharmacology.

[28]  I. Xanthopoulou,et al.  Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  I. Xanthopoulou,et al.  Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Maegan S. Reynolds.  Chronic Kidney Disease and Risk for Presenting with Acute Myocardial Infarction versus Stable Exertional Angina in Adults with Coronary Heart Disease , 2012 .

[31]  Christopher W. Good,et al.  Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial , 2012, Circulation. Cardiovascular interventions.

[32]  C. Cannon,et al.  Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). , 2011, The American journal of cardiology.

[33]  A. Go,et al.  Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. , 2011, Journal of the American College of Cardiology.

[34]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[35]  S. Pocock,et al.  Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI , 2011, JACC. Cardiovascular interventions.

[36]  P. Pais,et al.  The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. , 2011, Journal of the American College of Cardiology.

[37]  M. Flather,et al.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. , 2011, Journal of the American Society of Nephrology : JASN.

[38]  Brian K. Lee,et al.  Weight Trimming and Propensity Score Weighting , 2011, PloS one.

[39]  Ching-Lan Cheng,et al.  Validation of the national health insurance research database with ischemic stroke cases in Taiwan , 2011, Pharmacoepidemiology and drug safety.

[40]  M. Keltai,et al.  Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2010 .

[41]  K. Alexander,et al.  Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Report From the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network R , 2010, Circulation.

[42]  David Dai,et al.  Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. , 2009, JAMA.

[43]  P. Steg,et al.  Results of the PLATelet Inhibition and Patient Outcomes (PLATO) Trial , 2009 .

[44]  D. Kereiakes,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[45]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[46]  D. Holmes,et al.  Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. , 2009, Journal of the American College of Cardiology.

[47]  Deepak L. Bhatt,et al.  Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). , 2009, The American journal of cardiology.

[48]  M. Raebel,et al.  Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[49]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[50]  R. Califf,et al.  The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.

[51]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[52]  E. Schiffrin,et al.  Chronic Kidney Disease: Effects on the Cardiovascular System , 2007, Circulation.

[53]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[54]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[55]  S. Yusuf,et al.  Renal function and outcomes in acute coronary syndrome: impact of clopidogrel , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[56]  P. Morange,et al.  High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome , 2006, Journal of thrombosis and haemostasis : JTH.

[57]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[58]  Lakshminarayan Yerra,et al.  The renal patient with cardiovascular disease--no longer a simple plumbing problem. , 2005, Tennessee medicine : journal of the Tennessee Medical Association.

[59]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[60]  P. Stenvinkel,et al.  Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. , 2003, Journal of the American Society of Nephrology : JASN.

[61]  M. Gawaz,et al.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.

[62]  K. Eagle,et al.  Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. , 2003, Journal of the American Society of Nephrology : JASN.

[63]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[64]  A. Collins,et al.  Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.

[65]  H. Price.  Past and future , 1990, Nature.

[66]  Yoshio Kobayashi,et al.  High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. , 2019, Journal of cardiology.

[67]  N. Toma.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. , 2010, Maedica.

[68]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.